A Study to Evaluate the Efficacy and Tolerability of Rizatriptan for Treatment of Acute Migraine in Children and Adolescents (MK-0462-082 AM7)

Inclusion Criteria

• Patient weighs at least 20 kg (44 pounds)
• Patient has had a history of migraine with or without aura > 6 months with >= 1 to 15 headache-days per month OR has taken medication for acute

headache on more than 10 days per month in any of the 3 months prior to screening

• Patient has uncontrolled high blood pressure, uncontrolled diabetes, human immunodeficiency virus (HIV), any

cancer, or any other significant disease

• Patient has a history or clinical evidence of cardiovascular problems or stroke
• Patient has either demonstrated hypersensitivity to or experienced a serious

adverse event in response to rizatriptan

• Patient did not experience satisfactory relief from migraine pain to prior treatment with 2 or more adequate courses of 5-hydroxytryptamine 1 (5HT1) agonists
• Patient has a recent history (within the past year) or current evidence of drug or alcohol abuse or is a "recreational user" of illicit drugs
• Patient is currently taking monoamine oxidase inhibitors, methysergide, selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs) or propranolol, and is unable to tolerate withdrawal of these medications for the intervals required
• Patient is currently participating or has participated in a study with an

investigational compound or device within 30 days of screening

• Patient is legally or mentally incapacitated.